Kopran Ltd.

KOPRAN

₹136.22

-2.22% (-3.09)

Market Cap

₹658 Cr.

P/E

39.77

Key Ratios

Edit Ratio's

Market cap

658 Cr

39.77

Prom Holding

44.42 %

ROE (%)

7.44

ROCE (%)

11.04

Div Yield (%)

2.20

Sales

619 Cr

OPM (%)

7.05 %

Debt to Equity

0.29

Edit Ratio's

About

Kopran Limited specializes in manufacturing both Active Pharmaceutical Ingredients and Finishe… Read more

Low

120

52W Range

High

214

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

6 Yes

Positive for this company

2 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Capex vs ROCE

Roce of the company has decreased even without significant capex
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Share price

Share price has increased over last 10 years but more due to rerating
Working Capital

Company has significant working capital which is dragging its roce and roe
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Revenue mix

Product Wise Break-Up

Location Wise Break-Up - Formulation Business

Location Wise Break-Up

Therapeutic Area Break-Up

Dosage Form Break-Up

Asset Break-Up

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Aarti Drugs Ltd.

FAQs on Kopran Ltd. Business

What does Kopran do?

Kopran Limited is a pharmaceutical company that manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms, with a wide range of products for international markets. It also offers specialty products and operates subsidiaries in research and life sciences.

Who are the competitors of Kopran?

Kopran major competitors are Shree Ganesh Remed., Themis Medicare, Haleos Labs, Everest Organics, Nectar Lifesciences, Bajaj Healthcare, Smruthi Organics.
Market Cap of Kopran is ₹673 Crs.
While the median market cap of its peers are ₹413 Crs.

Is Kopran financially stable compared to its competitors?

Kopran seems to be less financially stable compared to its competitors.
Altman Z score of Kopran is 3.28 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release		Mar	Dec
Investor Presentation	Jan	May Jul Nov	Mar Jun Sep Dec	Sep Dec	Mar May	Mar Sep	Sep Dec
Conference Call		Mar	Mar Jun Sep Dec	Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Kopran Ltd.

Kopran Ltd. - Complete In depth Analysis - School Of Investing

View the discussion on ValuePickr - ValuePickr

Pharmaceuticals

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Nutraceuticals- Industry Overview - Value Educator

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Pharma Compliance In-Depth - Amit Rajan

Deep Dive into Pharma Sector - Omkara Capital

How The Pharma Industry Works - PPFAS

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Kopran Ltd.

Kopran Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

6 Yes

2 Neutral

9 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Promoter Holding

Retail Holding

Revenue Recognition

Price & Performance

ROE

Debt

Balance Sheet Strength

Capex vs ROCE

Current vs Historic Valuation

Share price

Working Capital

Sales Growth

Margin Stability

ROCE Strength

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up - Formulation Business

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up

UNLOCK PREMIUM

Dosage Form Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

Peer Comparison

Corporate Actions

Suppliers

FAQs on Kopran Ltd. Business

What does Kopran do?

Who are the competitors of Kopran?

Is Kopran financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE